Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals Inc (NQ: RCKT )

16.75 +0.96 (+6.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 913,987
Open 16.04
Bid (Size) 16.76 (3)
Ask (Size) 16.77 (16)
Prev. Close 15.79
Today's Range 15.79 - 16.79
52wk Range 7.565 - 23.48
Shares Outstanding 65,837,894
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma COO On Observing Rare Disease Day, And Why It Deserves US Attention
Feb. 28 is Rare Disease Day. It's meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia,... 
Via Benzinga

Performance

YTD
-12.58%
-12.58%
1 Month
-9.26%
-9.26%
3 Month
-7.61%
-7.61%
6 Month
+17.13%
+17.13%
1 Year
+0.48%
+0.48%

More News

Read More
What 6 Analyst Ratings Have To Say About Rocket Pharmaceuticals
Via Benzinga
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
From Rocket Pharmaceuticals, Inc.
Via Business Wire
The Latest Analyst Ratings for Rocket Pharmaceuticals
Via Benzinga
Where Rocket Pharmaceuticals Stands With Analysts
Via Benzinga
Expert Ratings for Rocket Pharmaceuticals
Via Benzinga
SVB Leerink Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Via MarketBeat
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
Nasdaq Down Over 3%; IsoPlexis Shares Spike Higher
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Tumbles 300 Points; US Economy Expands 3.2% In Q3
Via Benzinga
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Completes Acquisition of Renovacor
From Rocket Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why DraftKings Shares Are Trading Lower By 5%; Here Are 24 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.